Sanofi reports sales jump for Beyfortus as RSV antibody challenger from Merck nears
As Sanofi declares strong early sales for Beyfortus in its second RSV season, the French pharma is confident that it would still come out on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
